Jyong Biotech Ltd
Research Jyong Biotech Ltd (MENS) on Bullrun: market cap USD 155.89M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMENS
- ExchangeNASDAQ
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 155.89M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 4.67M
- Free cash flow-USD 3.04M
Valuation Snapshot
latest market cap is USD 155.89M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 4.67M | -USD 3.04M | n/a | -0.06 | USD 1.18M | USD 17.46M | -USD 24.91M |
| FY2024 | USD 0 | -USD 3.02M | -USD 3.62M | n/a | -0.04 | USD 101.00K | USD 18.14M | -USD 36.52M |
| FY2023 | USD 0 | -USD 4.40M | -USD 2.60M | n/a | -0.06 | USD 1.74M | USD 16.69M | -USD 34.07M |
| FY2022 | USD 0 | -USD 6.63M | -USD 3.22M | n/a | -0.09 | USD 718.00K | USD 14.25M | -USD 29.63M |
| FY2021 | USD 0 | -USD 4.20M | -USD 2.12M | n/a | -0.06 | USD 551.00K | USD 11.79M | -USD 23.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 155.89M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 293.22M | n/a | n/a | n/a |
About Jyong Biotech Ltd
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jyong Biotech Ltd's market cap?
Jyong Biotech Ltd's market capitalization is USD 155.89M.
What does Jyong Biotech Ltd do?
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.